AbbVie Reports Positive Phase 3 Venetoclax Data for CLL at EHA 2026

AbbVie Inc. (NYSE:ABBV) announced topline Phase 3 data from the CLL14 trial of its fixed-duration venetoclax-based combination therapy at the European Hematology Association (EHA) 2026 Congress on June 19. The results affirm venetoclax's enduring safety and efficacy in untreated chronic lymphocytic leukemia (CLL).

Trial Details

The CLL14 trial evaluated venetoclax plus obinutuzumab in previously untreated CLL patients. The data showed significant improvement in progression-free survival and a favorable safety profile.

Significance

These results strengthen venetoclax's position as a frontline treatment option for CLL, particularly with a fixed-duration regimen that reduces long-term toxicity.

Competitive Landscape

Venetoclax competes with BTK inhibitors like Imbruvica (Johnson & Johnson) and Calquence (AstraZeneca). The new data may support its use in broader patient populations.

Potential Impact on AbbVie

Venetoclax is a key growth driver for AbbVie, especially as Humira faces biosimilar competition. Positive CLL data could boost sales and extend its lifecycle.